ReviewExpert review of molecular diagnostics2011
Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer.
Review in Expert review of molecular diagnostics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Differentially expressed circulating miRNAs in postmenopausal osteoporosis: a meta-analysis.Bioscience reports · 2019Pooled it
- miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.Oncotarget · 2016Pooled it
- miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients.International journal of molecular sciences · 2023Article
- Identification of key differentially expressed mRNAs and microRNAs in non-small cell lung cancer using bioinformatics analysis.Experimental and therapeutic medicine · 2020Article
- Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies.Research and reports in urology · 2019Review
- Article
- miR-202 Inhibits Cell Proliferation, Migration, and Invasion by Targeting Epidermal Growth Factor Receptor in Human Bladder Cancer.Oncology research · 2018Article
- Identification of potential prognostic microRNA biomarkers for predicting survival in patients with hepatocellular carcinoma.Cancer management and research · 2018Article
- MicroRNA-146a affects the chemotherapeutic sensitivity and prognosis of advanced gastric cancer through the regulation of LIN52.Oncology letters · 2017Article
- miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.Molecular medicine reports · 2016Article
- MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016Article
- MicroRNA regulons in tumor microenvironment.Oncogene · 2015Review
- Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.International journal of clinical and experimental pathology · 2015Article
- Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer.The American journal of pathology · 2014Article
- Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine?Expert review of molecular diagnostics · 2014Review
- miR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma.Biomedical reports · 2014Article
- Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.Diagnostic pathology · 2013Article
- The role of noncoding RNA in hepatocellular carcinoma.Gland surgery · 2013Review
- Comprehensive microRNA Profiling of Prostate Cancer.Journal of Cancer · 2013Article
- MiRNA-429 suppresses the growth of gastric cancer cells in vitro.Journal of biomedical research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The promise of personalized medicine is highly dependent on the identification of biomarkers that inform diagnostic decisions and treatment options, as well as on the accurate, rapid and cost-effective detection and interpretation of these biomarkers. miRNAs, which are short noncoding regulatory RNAs, are rapidly emerging as a novel class of biomarkers with a unique set of biological and chemical properties that makes them very appealing candidates for theranostic applications in cancer. Since the utility of some protein-encoding gene biomarkers is already exploited in routine clinical practice, it will be important to identify areas in which miRNAs provide complementary or superior information to these existing (and other translational) biomarkers to enhance the diagnostic, prognostic and predictive power of molecular characterization of tumors. In this article, the challenges and opportunities for integration of miRNA-based assays in the clinical toolkit to improve care and management of patients afflicted with solid tumors will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.